文献速递消化、代谢与肾脏急症心脑血管急症重症综合管理与镇静镇痛

保留比值受损肺功能与2型糖尿病患者大血管、微血管并发症及死亡风险

Preserved Ratio Impaired Spirometry and Risks of Macrovascular, Microvascular Complications and Mortality Among Individuals With Type 2 Diabetes.
PubMed 文献 · Chest · 2023-06-17
一句话结论在2型糖尿病患者中,保留比值受损肺功能(PRISm)与卒中、心梗、视网膜病变、肾病及全因和心血管死亡风险升高相关,并可改善基于诊室的风险评分的重分类能力。

本研究基于英国生物银行(UK Biobank)队列20,047例2型糖尿病(T2D)患者,评估基线保留比值受损肺功能(PRISm,FEV1/FVC≥0.70且FEV1<预计值80%)与后续大血管、微血管并发症及死亡风险的前瞻性关联。中位随访11.52至11.87年期间,4,521例(22.55%)存在PRISm。校正后PRISm与卒中(任何类型)HR 1.413(95%CI 1.187-1.681)、缺血性卒中HR 1.382(95%CI 1.129-1.690)、心肌梗死HR 1.253(95%CI 1.045-1.503)、冠心病HR 1.206(95%CI 1.086-1.339)、糖尿病视网膜病变HR 1.311(95%CI 1.141-1.506)、糖尿病肾病HR 1.384(95%CI 1.190-1.610)、全因死亡HR 1.337(95%CI 1.213-1.474)、心血管死亡HR 1.597(95%CI 1.296-1.967)及呼吸死亡HR 1.559(95%CI 1.189-2.044)风险升高相关。将PRISm加入基于诊室的风险评分后,基于净重分类指数的重分类能力显著改善15.53%(95%CI 10.14%-19.63%)至33.60%(95%CI 20.90%-45.79%)。

要点

  • 在20,047例T2D患者中,22.55%(4,521例)基线存在PRISm(FEV1/FVC≥0.70且FEV1<预计值80%)。
  • 中位随访11.52至11.87年,PRISm组较肺功能正常组卒中(任何类型)风险HR 1.413(95%CI 1.187-1.681)、缺血性卒中HR 1.382(95%CI 1.129-1.690)。
  • PRISm组心肌梗死HR 1.253(95%CI 1.045-1.503)、冠心病HR 1.206(95%CI 1.086-1.339)、糖尿病视网膜病变HR 1.311(95%CI 1.141-1.506)、糖尿病肾病HR 1.384(95%CI 1.190-1.610)。
  • PRISm组全因死亡HR 1.337(95%CI 1.213-1.474)、心血管死亡HR 1.597(95%CI 1.296-1.967)、呼吸死亡HR 1.559(95%CI 1.189-2.044)。
  • 将PRISm加入基于诊室的风险评分,净重分类指数改善15.53%(95%CI 10.14%-19.63%)至33.60%(95%CI 20.90%-45.79%)。

适用人群与场景

  • 来自英国生物银行队列的20,047例2型糖尿病患者,招募时具有完整肺功能检查数据。
  • 基线存在PRISm者4,521例(占22.55%),其余为肺功能正常者。

诊断标准与关键阈值

  • PRISm定义:FEV1与FVC比值≥0.70,且FEV1<预计值80%。

研究设计与关键结果

  • 研究类型:基于英国生物银行队列的队列分析;样本量20,047例2型糖尿病患者;基线PRISm者4,521例(22.55%)。
  • 中位随访11.52至11.87年,采用多变量Cox比例风险模型评估基线PRISm与结局的关联。
  • PRISm组较肺功能正常组:卒中(任何类型)HR 1.413(95%CI 1.187-1.681),缺血性卒中HR 1.382(95%CI 1.129-1.690),心肌梗死HR 1.253(95%CI 1.045-1.503),冠心病HR 1.206(95%CI 1.086-1.339)。
  • PRISm组较肺功能正常组:糖尿病视网膜病变HR 1.311(95%CI 1.141-1.506),糖尿病肾病HR 1.384(95%CI 1.190-1.610)。
  • PRISm组较肺功能正常组:全因死亡HR 1.337(95%CI 1.213-1.474),心血管死亡HR 1.597(95%CI 1.296-1.967),呼吸死亡HR 1.559(95%CI 1.189-2.044)。
  • 将PRISm加入基于诊室的风险评分后,基于净重分类指数的重分类能力改善15.53%(95%CI 10.14%-19.63%)至33.60%(95%CI 20.90%-45.79%)。

证据类型、等级与局限

  • 证据类型:基于英国生物银行队列的队列分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 在2型糖尿病患者中,PRISm可能作为不良预后(大血管、微血管并发症及死亡)的预测因素,并可能改善基于诊室的风险评分的重分类能力。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: The prospective associations of preserved ratio impaired spirometry (PRISm) with new-onset macrovascular and microvascular complications and mortality among individuals with type 2 diabetes (T2D) and whether PRISm enhances the prediction ability of an established office-based risk score remain to be elucidated.

RESEARCH QUESTION: Can PRISm be used as a predictor of poor prognosis in individuals with T2D?

STUDY DESIGN AND METHODS: We included 20,047 study participants with T2D and complete data on spirometry at recruitment from the UK Biobank cohort. Multivariable Cox proportional hazards models were used to assess the associations of baseline PRISm (FEV1 to FVC ratio, ≥ 0.70; FEV1, < 80% predicted) with subsequent risks of incident stroke (any type), ischemic stroke, myocardial infarction, unstable angina, coronary heart disease, diabetic retinopathy, diabetic kidney disease, all-cause mortality, cardiovascular mortality, and respiratory mortality.

RESULTS: For this cohort analysis, 4,521 patients (22.55% of participants with T2D) showed comorbid PRISm at baseline. Over a median follow-up of 11.52 to 11.87 years, patients with T2D with PRISm at baseline showed higher risks than those with normal spirometry findings of various T2D complications developing and mortality; the adjusted hazard ratios for PRISm were 1.413 (95% CI, 1.187-1.681) for stroke (any type), 1.382 (95% CI, 1.129-1.690) for ischemic stroke, 1.253 (95% CI, 1.045-1.503) for myocardial infarction, 1.206 (95% CI, 1.086-1.339) for coronary heart disease, 1.311 (95% CI, 1.141-1.506) for diabetic retinopathy, 1.384 (95% CI, 1.190-1.610) for diabetic kidney disease, 1.337 (95% CI, 1.213-1.474) for all-cause mortality, 1.597 (95% CI, 1.296-1.967) for cardiovascular mortality, and 1.559 (95% CI, 1.189-2.044) for respiratory mortality, respectively. The addition of PRISm significantly improved the reclassification ability, based on the net reclassification index, of an office-based risk score by 15.53% (95% CI, 10.14%-19.63%) to 33.60% (95% CI, 20.90%-45.79%).

INTERPRETATION: Individuals with T2D with comorbid PRISm, accounting for a considerable proportion of the population with T2D, showed significantly increased risks of adverse macrovascular and microvascular complications and mortality.

来源:Chest,查看原文。版权归原作者所有。

参考来源

  1. Li G, Jankowich MD, Wu L, et al. Preserved Ratio Impaired Spirometry and Risks of Macrovascular, Microvascular Complications and Mortality Among Individuals With Type 2 Diabetes. Chest. 2023. PMID: 37356807. doi:10.1016/j.chest.2023.05.031

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。